Zulvac BTV
Bluetongue virus vaccine (inactivated) (multistrain: 1 strain out of a set of 3)
Table of contents
Overview
Zulvac BTV is a veterinary vaccine used in sheep and cattle to protect them against bluetongue disease, an infection caused by the bluetongue virus, which is transmitted by midges.
The vaccine contains inactivated (killed) bluetongue virus. When used in sheep or cattle the vaccine contains one of the following three vaccine strains: BTV serotype 1, BTV serotype 4 and BTV serotype 8. The serotype to be used in the vaccine is selected before manufacture depending on which type is circulating and causing disease at the time.
The vaccine can prevent the presence of serotypes 1 or 8 and reduce levels of serotype 4 in the blood in sheep, and prevent the presence of serotypes 1, 4 or 8 in the blood in cattle.
Authorisation details
Product details | |
---|---|
Name |
Zulvac BTV
|
Agency product number |
EMEA/V/C/004185
|
Active substance |
One of the following inactivated bluetongue virus strains:Inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02Inactivated bluetongue virus, serotype 4, strain SPA-1/2004
|
International non-proprietary name (INN) or common name |
Bluetongue virus vaccine (inactivated) (multistrain: 1 strain out of a set of 3)
|
Species |
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI02AA
|
Publication details | |
---|---|
Marketing-authorisation holder |
Zoetis Belgium SA
|
Revision |
2
|
Date of issue of marketing authorisation valid throughout the European Union |
25/04/2017
|
Contact address |
Rue Laid Burniat 1 |
Product information
20/05/2021 Zulvac BTV - EMEA/V/C/004185 - II/0004
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Immunologicals
-
Immunologicals for bovidae
-
Inactivated viral vaccines
-
bluetongue virus
-
SHEEP
Therapeutic indication
Active immunisation of sheep from 6 weeks of age for the prevention of viraemia caused by bluetongue virus, serotypes 1 and 8, and for the reduction of viraemia caused by bluetongue virus, serotype 4 and active immunisation of cattle from 12 weeks of age for the prevention of viraemia caused by bluetongue virus, serotypes 1 and 8.